Cepheid, a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests, has ...

The development of the Xpert MTB/RIF assay has been the most important breakthrough for the diagnosis of tuberculosis in decades. David L. Cohn This molecular-based test provides a rapid and sensitive ...

Cepheid ($CPHD) says it gained a key "moderate complexity" CLIA designation for its new combo TB test, helping to position the diagnostic to reach the broadest ...

The US Food & Drug Administration (FDA) has categorized Cepheid's Xpert MTB/RIF test as 'Moderate Complexity' under the Clinical Laboratory Improvement Amendments (CLIA). Xpert MTB/RIF is designed for ...

The U.S. Food and Drug Administration (FDA) today granted marketing approval for Cepheid’s Xpert MTB/RIF Assay, making it the “first FDA-reviewed test that can simultaneously detect bacteria that ...

An automated molecular test for Mycobacterium tuberculosis and rifampin resistance identified 98.2% of patients with smear-positive tuberculosis and 72.5% of patients with smear-negative tuberculosis.

Cepheid's Xpert MTB/RIF test is designed for use on the company's GeneXpert Systems and can be used for rapid molecular detection of Mycobacterium tuberculosis complex (MTB-complex) DNA. Further, the ...

Background: The identification of non-tuberculosis (TB) mycobacterial (NTM) infection remains a significant challenge. This study aims to investigate the diagnostic value of multicolour nested ...